Accent Therapeutics, Inc. is a clinical-stage biopharmaceutical company pioneering novel, targeted, small molecule cancer therapeutics. Leveraging expertise in RNA-modifying proteins (RMPs) and the systemic mapping of both the RMP space and adjacent high-value areas for drug discovery, Accent employs a flexible model that allows for a diversity of approaches to developing potentially transformative biomarker-driven cancer medicines. Accent is advancing innovative treatments designed for both novel and known, but suboptimally-addressed, high-impact oncology targets offering the potential to benefit large patient populations with significant unmet need. The company’s clinical-stage assets include ATX-559, a first-in-class DHX9 inhibitor, and ATX-295, a potentially best-in-class KIF18A inhibitor, both of which are currently being evaluated in Phase 1/2 clinical trials. MassBio Member Spotlight: Accent Therapeutics, Inc. Location: Lexington, MA Website: accenttx.com Leadership: Shakti Narayan, PhD, JD | Chief Executive Officer Serena Silver, PhD | Chief Scientific Officer Jason Sager, MD | Chief Medical Officer David Brower, MBA | Chief Business Officer and Head of Finance Therapeutic Area: Oncology https://lnkd.in/e55Hg4iA | #PatientDriven #MassBioMember #MassBioMembers
